Synergistic Neutralization of Rubella Virus by Monoclonal Antibodies to Viral Haemagglutinin

Gerna, Giuseppe; Revello, Maria Grazia; Dovis, M.; Petruzzelli, E.; Achilli, G; Percivalle, Elena; Torsellini, Maria

doi:10.1099/0022-1317-68-7-2007

Cited by 21 publications

(9 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As alluded to several times in preceding discussions, several panels of monoclonal antibodies have been raised against rubella virus (Tedder et al, 1982;Waxham and Wolinsky, 1985a;Umino et al, 1985;Green and Dorsett, 1986;Ho-Terry et al, 1986;Gerna et al, 1987). In these panels, the greatest number of monoclonal antibodies is specific for E l and, depending on the panel, three to six epitopes on E l were defined.…”

Section: E Immunological Determinants On Virion Proteinsmentioning

confidence: 99%

Molecular Biology of Rubella Virus

Frey

1994

Advances in Virus Research

253

251

View full text Add to dashboard Cite

Section: E Immunological Determinants On Virion Proteinsmentioning

confidence: 99%

Molecular Biology of Rubella Virus

Frey

1994

Advances in Virus Research

253

251

View full text Add to dashboard Cite

“…To circumvent these ambiguities, combinations of MAbs could be studied, but there are few data concerning the ability of MAb combinations to neutralize primary isolates, a result, in part, of the paucity of human MAbs isolated from HIV-1-infected individuals which are able to neutralize primary isolates. However, it has been shown with other viruses that neutralizing activity can be conferred by combinations of two non-neutralizing MAbs or by one NMAb and one non-NMAb (2,26,34,59). Consequently, a study of HIV-1 neutralization was undertaken using pairs of human MAbs directed against gp120 or gp41, whether of two NMAbs or of one NMAb and one non-NMAb.…”

mentioning

confidence: 99%

Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6

Verrier¹,

Nádas

Gorny³

et al. 2001

J Virol

View full text Add to dashboard Cite

Human immunodeficiency virus-type I (HIV-1) infection elicits antibodies (Abs) directed against several regions of the gp120 and gp41 envelope glycoproteins. Many of these Abs are able to neutralize T-cell-lineadapted strains (TCLA) of HIV-1, but only a few effectively neutralize primary HIV-1 isolates. The nature of HIV-1 neutralization has been carefully studied using human monoclonal Abs (MAbs), and the ability of such MAbs to act in synergy to neutralize HIV-1 has also been extensively studied. However, most synergy studies have been conducted using TCLA strains. To determine the nature of Ab interaction in HIV-1 primary isolate neutralization, a panel of 12 anti-HIV-1 human immunoglobulin G (IgG) MAbs, specific for epitopes in gp120 and gp41, were used. Initial tests showed that six of these MAbs, as well as sCD4, used individually, were able to neutralize the dualtropic primary isolate HIV-1 89.6 ; MAbs giving significant neutralization at 2 to 10 g/ml included 2F5 (anti-gp41), 50-69 (anti-gp41), IgG1b12 (anti-gp120 CD4bd ), 447-52D (anti-gp120 V3 ), 2G12 (antigp120), and 670-D (anti-gp120 C5 ). For studies of reagent interaction, 16 binary combinations of reagents were tested for their ability to neutralize HIV-1 89.6 . Reagent combinations tested included one neutralizing MAb with sCD4, six pairs consisting of two neutralizing MAbs, and nine pairs consisting of one neutralizing MAb with another non-neutralizing MAb. To assess the interaction of the latter type of combination, a new mathematical treatment of reagent interaction was developed since previously used methods could be used only when both reagents neutralize. Synergy was noted between sCD4 and a neutralizing anti-gp120 V3 MAb. Antagonism was noted between two pairs of anti-gp41 MAbs (one neutralizing and one non-neutralizing). All of the other 13 pairs of MAbs tested displayed only additive effects. These studies suggest that Abs rarely act in synergy to neutralize primary isolate HIV-1 89.6

show abstract

“…Antigenic and functional properties of these structural polypeptides have been studied with monoclonal antibodies. At least six antigenic sites have been identified in El (Gerna et al, 1987a;Waxham and Wolinsky, 1985b). Four sites are associated with hemagglutinating activity; two of these sites have hemolysin activity, and one is associated with neutralization.…”

Section: Morphology and Antigensmentioning

confidence: 98%

Togaviridae: Rubella Virus

Best¹,

O’Shea²

1988

Laboratory Diagnosis of Infectious Diseases Principles and Practice

View full text Add to dashboard Cite

Disease: Rubella, congenital rubella. Etiologic Agent: Rubella virus, genus Rubivirus of Togaviridae. Clinical Manifestations: Asyptomatic infections are common; fever with rash; lymphadenitis; arthropathy and arthritis in adults. Congenital infection may result in fetal death and spontaneous abortion, live birth of severely malformed infant, an infant with minimal damage, or a healthy infant. Pathology: Primary site of virus replication is the nasopharyngeal mucosa, followed by spread of virus to local lymph nodes and a viremia 7 days after infection. The appearance of a rash may be caused by viral antigen-antibody complexes. During pregnancy, the virus infects the placenta and is then disseminated to all fetal tissues. Laboratory Diagnosis: IgG serology in paired serum specimens; IgM serology in a single serum. IgG serology is in large-scale use for immunity testing. Epidemiology: Worldwide distribution; endemic in temperate climates, with seasonal peaks during spring and early summer. In countries with successful childhood vaccination programs, major epidemics have been prevented.

show abstract

Synergistic Neutralization of Rubella Virus by Monoclonal Antibodies to Viral Haemagglutinin

Cited by 21 publications

References 17 publications

Molecular Biology of Rubella Virus

Molecular Biology of Rubella Virus

Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6

Togaviridae: Rubella Virus

Contact Info

Product

Resources

About